Lexeo Research Development from 2010 to 2026

LXEO Stock   7.44  0.10  1.33%   
Lexeo Therapeutics Research Development yearly trend continues to be very stable with very little volatility. Research Development is likely to drop to about 49.7 M. During the period from 2010 to 2026, Lexeo Therapeutics Research Development quarterly data regression pattern had sample variance of 818.9 T and median of  4,318,765. View All Fundamentals
 
Research Development  
First Reported
2010-12-31
Previous Quarter
85.2 M
Current Value
49.7 M
Quarterly Volatility
28.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Lexeo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexeo Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 9 M or Depreciation And Amortization of 2.4 M, as well as many indicators such as Price To Sales Ratio of 377, Dividend Yield of 0.0 or PTB Ratio of 1.69. Lexeo financial statements analysis is a perfect complement when working with Lexeo Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Lexeo Stock
Check out the analysis of Lexeo Therapeutics Correlation against competitors.

Latest Lexeo Therapeutics' Research Development Growth Pattern

Below is the plot of the Research Development of Lexeo Therapeutics Common over the last few years. It is Lexeo Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexeo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Lexeo Research Development Regression Statistics

Arithmetic Mean23,758,593
Geometric Mean10,783,218
Coefficient Of Variation120.45
Mean Deviation25,157,424
Median4,318,765
Standard Deviation28,616,300
Sample Variance818.9T
Range80.9M
R-Value0.82
Mean Square Error287.6T
R-Squared0.67
Significance0.000058
Slope4,641,099
Total Sum of Squares13102.3T

Lexeo Research Development History

202649.7 M
202585.2 M
202474.1 M
202353.1 M
202249.2 M
202145.1 M

About Lexeo Therapeutics Financial Statements

Lexeo Therapeutics investors utilize fundamental indicators, such as Research Development, to predict how Lexeo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Research Development85.2 M49.7 M

Pair Trading with Lexeo Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lexeo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexeo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Lexeo Stock

  0.55CING CingulatePairCorr
The ability to find closely correlated positions to Lexeo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lexeo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lexeo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lexeo Therapeutics Common to buy it.
The correlation of Lexeo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lexeo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lexeo Therapeutics Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lexeo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lexeo Therapeutics Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lexeo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lexeo Therapeutics Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lexeo Therapeutics Common Stock:
Check out the analysis of Lexeo Therapeutics Correlation against competitors.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Will Biotechnology sector continue expanding? Could Lexeo diversify its offerings? Factors like these will boost the valuation of Lexeo Therapeutics. Expected growth trajectory for Lexeo significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lexeo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(2.50)
Return On Assets
(0.45)
Return On Equity
(0.81)
Investors evaluate Lexeo Therapeutics Common using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Lexeo Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Lexeo Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Lexeo Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lexeo Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Lexeo Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.